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Abstract
Abnormal activation of the canonical Wnt signaling pathway has been implicated in carcinogenesis. Transcription of Wnt
target genes is regulated by nuclear b-catenin, whose over-expression is observed in Hepatocellular Carcinoma (HCC) tissue.
Cyr61, a member of the CCN complex family of multifunctional proteins, is also found over-expressed in many types of
tumor and plays dramatically different roles in tumorigenesis. In this study, we investigated the relationship between Cyr61
and b-catenin in HCC. We found that while Cyr61 protein was not expressed at a detectable level in the liver tissue of
healthy individuals, its expression level was elevated in the HCC and HCC adjacent tissues and was markedly increased in
cancer-adjacent hepatic cirrhosis tissue. Over-expression of Cyr61 was positively correlated with increased levels of b-
catenin in human HCC samples. Activation of b-catenin signaling elevated the mRNA level of Cyr61 in HepG2 cells, while
inhibition of b-catenin signaling reduced both mRNA and protein levels of Cyr61. We identified two TCF4-binding elements
in the promoter region of human Cyr61 gene and demonstrated that b-catenin/TCF4 complex specifically bound to the
Cyr61 promoter in vivo and directly regulated its promoter activity. Furthermore, we found that over-expression of Cyr61 in
HepG2 cells promoted the progression of HCC xenografts in SCID mice. These findings indicate that Cyr61 is a direct target
of b-catenin signaling in HCC and may play an important role in the progression of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
malignancy and the third deadliest cancer worldwide. Nearly 78%
of the global HCC were reported in Asian countries [1].
According to the WHO report, China has the highest incidence
and mortality of HCC in the world. Since the 1990s, HCC has
become the second leading cause of cancer death in China.
Multiple factors and signaling pathways have been shown to
contribute to the tumorigenesis of HCC [2]. Wnt/b-catenin
signaling pathway plays an essential role in all phases of liver
development and maturation. The aberrant activation of canon-
ical Wnt/b-catenin signaling was shown to contribute to the HCC
development [3,4,5]. In the absence of Wnt, intracellular b-
catenin is either bound to cadherins at cell adhesion junctions or
rapidly degraded in the cytosol by a multi-protein complex
consisting of b-catenin, glycogen synthase kinase-3b (GSK-3b),
adenomatous polyposis coli (APC), and Axin. When Wnt binds to
the cell surface receptor, GSK-3b is inactivated, thereby releases
b-catenin, which translocates to the nucleus, binds to T-cell factor
4/lymphocyte enhancer factor (TCF4/LEF), and targets Wnt-
responsive genes. Several known Wnt/b-catenin target genes were
found being expressed in HCC, including NOTUM [6], GS [7]
and TBX3 [8]. Moreover, 33 novel candidate target genes were
discovered expressed in hepatoma cells and were considered to be
involved in multiple biological processes such as signaling
transduction, inflammation, cell growth, proliferation and protein
biosynthesis [9].
Cysteine-rich protein 61 (Cyr61/CCN1), a member of the CCN
growth factor family, is a secreted, integrin-binding protein that
regulates multiple cellular activities such as cell adhesion,
migration, proliferation, survival and apoptosis [10]. Alterations
in expression of Cyr61 were seen in many human tumors;
however, its role varies in different tumor types [11]. Cyr61 was
shown in some studies to promote tumorigenesis, progression and
invasion in cancers including gliomas [12], gastric cancer [13],
breast cancer [14], and prostatic carcinoma [15]. On the other
hand, it was found to play roles such as inducing apoptosis,
inhibiting tumor growth in non-small-cell lung cancer [16], cervix
cancer [17] and endometrial cancer [18]. Its role in HCC is also
controversial. While some laboratories showed that Cyr61 was
down-regulated in HCC and that Cyr61 suppressed cell
proliferation in HCC cell lines [19,20], others found that
expression of Cyr61 was not significantly different in HCC tissue
compared to surrounding non-tumor tissue [21]. There is also a
study showing that Cyr61 is over-expressed in HCC tissue [22].
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family, namely CTGF/CCN2 and WISP-1/CCN4, are regulated
by Wnt/b-catenin signaling pathway [23,24]. Our previous studies
have demonstrated that Cyr61 is regulated by canonical Wnt
signaling in mesenchymal stem cells [25]. Other studies found that
Cyr61 can activate the b-catenin-TCF4 signaling pathway in
gliomas cells [26] and non-small-cell lung cancer [16]. So, the
relationship between Cyr61 and Wnt/b-catenin signaling pathway
is complex in different cells. However, it is not clearly illustrated in
HCC cell lines. In this report, we study the relationship between
Wnt/b-catenin signaling and Cyr61 expression in HCC. We
found that Cyr61 was over-expressed in HCC and its expression
levels were positively correlated with the activation of b-catenin
protein. Furthermore, we demonstrated that Cyr61 is a direct
target gene of b-catenin signaling in HepG2 cells and over-
expression of Cyr61 promotes the proliferation of HepG2 cells
both in vitro [27] and in vivo. Our finding strongly suggests that
Cyr61 is regulated by b-catenin in HCC and has multiple
functions in the genesis and the progression of HCC.
Results
Expression of Cyr61 protein in normal liver tissue, hepatic
cirrhosis, HCC and tumor-adjacent tissue
We previously reported that elevated Cyr61 mRNA levels were
found in the HCC tissue compared to those found in the normal
tissue by RT-PCR analysis. Moreover, we observed that the
expression of Cyr61 was closely associated with some clinical
manifestations, including the number of cancer nodules, degree of
tumor differentiation, and venous infiltration. However, the
expression did not correlate with some other clinical observations,
such as the size of tumor, metastasis, cancer embolus and AFP
concentration [28].
There are reports by other laboratories indicating that
expression of Cyr61 is down regulated or is not significantly
different in HCC tissue compared with that in the normal tissue
[19,21]. We analyzed a greater number of samples with a different
approach to look into the discrepancy. Immunohistochemistry
staining was employed to study the expression of Cyr61 protein in
normal liver tissue (n=5), hepatic cirrhosis of cancer-adjacent
tissue (n=30), HCC (n=62) and the HCC adjacent tissue (n=27).
We found that Cyr61 was expressed in 91.4% of HCC tissues and
in 97.6% of adjacent tissue. However, it was not expressed or
expressed at a very low level in normal liver tissue (Figure 1: A-1).
Cyr61 expression was significantly higher in HCC adjacent tissue
compared to tumor tissue (Figure 1: A-3; A-4, P,0.05), and was
mainly located in cytoplasm (Figure 1: A). In tumors at different
differentiation stages, the Cyr61 protein level was found
significantly higher in well-differentiated HCC than in the poorly
differentiated HCC (Figure 1: A-2; A-4, P,0.01). This phenom-
enon was also observed within the same tumor where stronger
staining was found in more differentiated tumor cells (Figure 1: A-
5). Furthermore, significant increases in Cyr61 expression levels
were observed in the cirrhotic tissues adjacent to HCC compared
to HCC itself (Figure 1: A-6, P,0.01).
Cyr61 over-expression is tightly linked to activated b-
catenin signaling in human HCC tissues
Expression of Cyr61 and b-catenin were negative or weak in
normal liver tissue (Figure 1: A-1; B-1). Similar to the changes of
expression level of Cyr61 in HCC and normal liver tissue, b-
catenin expression level in HCC and HCC adjacent tissue was
significantly increased in comparison to normal liver tissue
(Figure 1: B). b-catenin was mainly localized at the cell membrane
in HCC adjacent tissue (Figure 1: B-3), but it was also found
localized in the cytoplasm and/or nucleus in tumor tissue (Figure 1:
B-2). Cyr61 was localized in the cytoplasm of both tumor and
adjacent tissues (Figure 1: A). Our findings point to a positive
correlation between high Cyr61 expression level and over-
expression of b-catenin protein (r=0.793, P,0.01) (Figure 1C).
Cyr61 expression levels are influenced by the alteration
of b-catenin expression
The correlation of expression between b-catenin and Cyr61 in
HCC samples leads us to postulate that b-catenin may regulate
Cyr61 expression. HCC cell line HepG2 was used to determine
whether the expression of Cyr61 could be influenced by b-catenin.
We infected HepG2 cells with adenovirus expressing b-catenin,
and assessed the Cry61 mRNA levels at various time points post
infection. An increased expression of b-catenin was observed at 48,
72 and 96 hrs after adenovirus Adb-catenin infection, which was
not seen in cells infected with a control virus, AdGFP (Figure 2A).
Assessment of Cyr61 mRNA levels in the same samples revealed
that the expression of endogenous Cyr61 also increased at a
similar time course in the cells infected with Adb-catenin but not
the AdGFP virus (Figure 2B).
To further demonstrate that Cyr61 expression is directly related
to the levels of b-catenin, we studied the effect of reduced
expression of b-catenin on Cyr61 expression. HepG2 cells were
infected with adenovirus expressing siRNA for b-catenin (Adsib-
catenin) or non-specific siRNA (AdSES-hus), expression levels of
b-catenin as well as Cyr61 were assessed by RT-PCR and western
blot. We found that while both the mRNA and protein levels of b-
catenin were reduced by introducing b-catenin siRNA via
adenovirus, they were not affected by the non-specific siRNA
(Figure 3A, 3C). In cells where the b-catenin was knocked down by
siRNA, the mRNA and protein levels of Cyr61 were also
decreased, which was not seen in cells with intact b-catenin
level(Figure 3B, 3C). These data suggests that b-catenin may be
directly responsible for regulating Cyr61 expression.
b-catenin directly regulates the expression of Cyr61
We then studied whether b-catenin is directly responsible for
transcriptional activation of Cry61. b-catenin activates transcrip-
tion of its target genes through forming a protein complex with
TCF, which binds to the promoter region of the target genes. We
utilized a dominant negative form of TCF4(dnTCF4) that fails to
interact with b-catenin and results in decreased transactivation
activity for b-catenin/TCF4 complex and reduced target gene
expression. HepG2 cells were co-infected with Luciferase reporter
construct AdTOP-Luc and adenovirus expressing dnTCF4
(AddnTCF4) or control virus expressing GFP (AdGFP). A
significant down-regulation in TOP-Luc reporter activity was
apparent after cells were infected with AddnTCF4, but not the
control AdGFP, indicating that the transactivation activity of b-
catenin is inhibited in the presence of dnTCF4 (Figure 3D).
We assessed the expression levels of Cyr61 in these cells by
western blot. In cells infected with AddnTCF4, where the
transactivation activity of b-catenin was inhibited, the Cyr61
protein level was also reduced. This was not seen in cells infected
with control AdGFP where the b-catenin activity was not affected
(Figure 3E). These findings demonstrated that b-catenin/TCF4
regulates the expression of Cyr61.
It has been shown that a consensus TCF4 binding element
(TBE) is presented in the target genes of b-catenin/TCF4 complex
[29,30,31]. We identified two putative TBEs in the human Cyr61
promoter region. TBE1 (CTTTGAA) and TBE2 (AACTTTG)
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tion start site respectively (Figure 4A).
ChIP assay was employed to determine whether b-catenin/
TCF4 directly bind to the promoter region of Cyr61 in HepG2
cells. Agarose gel analysis of PCR products showed that anti-b-
catenin antibody effectively immunoprecipitated the Cyr61
promoter containing the two TBEs (Figure 4C, lane B). The
interaction between b-catenin and the Cyr61 promoter sequence
was specific, as only b-catenin antibody but not control IgG was
able to pull down the Cyr61 promoter DNA fragments (Figure 4C,
lane B,I).
To determine if over-expression of b-catenin affected Cyr61
promoter activity directly, the fragment extending from 2750 bp
to 2500 bp upstream of the transcriptional start site of human
Cyr61 promoter was cloned into pGL3 to generate a luciferase
reporter construct (pGL3-TBE). As shown in Figure 4D, over-
expression of b-catenin significantly activates Cyr61 promoter as
indicated by the increased luciferase activity compared with the
control in 293 cells. DnTCF4 was able to abrogate this activation
since the luciferase activity was greatly reduced in cells when Ad-
dnTCF4 was cotransfected with Adb-catenin.
Figure 1. Cyr61 and b-catenin protein expression in tissue samples are detected by immunohistochemistry. (A), A-1: Expression of
Cyr61 in normal liver tissues was negative (4006); Expression of Cyr61 in well-differentiated HCC (A-2) was higher than in poorly differentiated HCC
(A-4) (4006); A-3: Expression of Cyr61 was positive in HCC adjacent tissue (4006); A-5: Expression of Cyr61 in well-differentiated tumor regions (W)
was higher than poorly differentiated areas (P) at the same section (1006); A-6: Overexpression of Cyr61 in hepatic cirrhosis of adjacent cancer areas
(C), and loss of expression in HCC (T) (2006); W, well-differentiated tumor; P, poorly differentiated tumor; C, hepatic cirrhosis; T, tumor. (B), B-1:
Expression of b-catenin in normal liver tissues was negative; B-2: Expression of b-catenin in tumor tissue; B-3: Expression of b-catenin in HCC adjacent
tissue. (C), Correlation between Cyr61 and b-catenin protein expression levels. r=0.793, P,0.01.
doi:10.1371/journal.pone.0035754.g001
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Cyr61 gene transcription, site-directed mutation of one or double
TBE sites was generated in the context of pGL3 luciferase reporter
plasmid. Cyr61 promoter activity, which was increased by b-
catenin in 293 cells, was abrogated when one or both of the TBE
sites were mutated (Figure 4D). Cyr61 promoter activity was
decreased when either of the TBE site was mutated in HepG2 cell
lines (Figure 4E). And the promoter activity was markedly reduced
if both of the TBE1 and TBE2 sites were mutated (Figure 4E).
These data demonstrated that b-catenin activates Cyr61 promoter
directly.
Cyr61 promotes the growth of HCC xenografts in SCID
mice
Previously, we found that over-expressing the exogenous Cyr61
in HepG2 cells by recombinant adenovirus vector leads to
increased proliferation and migration ability in HepG2 cells
[27]. Our results suggested a role of Cyr61 in promoting HCC
tumor genesis. In this study, we further investigated the role of
Cyr61 on tumor growth in vivo with an animal model. HepG2 cells
were infected with AdRFP or AdCyr61 at the same infection ratio
for 36 hrs before subcutaneous implantation. Tumor sizes were
measured every 3 days after implantation. As seen in Figure 5B
and 5D, the tumor of HepG2 cells infected with AdCyr61 grew
significantly faster in vivo than that of the HepG2 cells infected with
AdRFP. Over-expression of Cyr61 increased the growth rate by
22% compared with the RFP control group (P=0.02). Specifically,
the doubling times for the tumor mass of Cyr61 over-expressed
cells and RFP control cells were 2.5360.16 days and 3.4760.27
days respectively in the HepG2 xenografts in SCID mice.
H&E staining of the xenograft tumor tissue revealed that there
were hyperplasia in fibrous connective tissue, infiltration of
inflammatory cells, and multinuclear tumor cells (Figure 5C). To
explore whether Cyr61 promotes HCC xenografts by inducing cell
proliferation, we assessed the expression of Ki-67, a nuclear
protein that is necessary for tumor cell proliferation, in HCC
xenograft tissue by immunohistochemical staining. The positive
staining of Ki-67 was stronger in the xenograft tissues from the
experimental group than those from the control group (Figure 5C).
Discussion
Given the importance of Wnt/b-catenin pathway in normal
embryonic and adult liver development, it is not surprising to see
that its activity is perturbed in HCC. About 50%–70% of HCC
are found to have an increased level of b-catenin in the cytoplasm
or nucleus, which is believed to provide growth advantage for
tumor cells. Many of the target genes of Wnt/b-catenin signaling
pathway are involved in promoting cell proliferation.
In the present study, we showed that Cyr61 is over-expressed in
HCC, and that it is one of the target genes for Wnt/b-catenin
pathway. We also demonstrated that increased expression of
Cyr61 promoted the growth of HepG2 cell xenografts in SCID
mice.
The roles of the Cyr61 in cancer development are complex. A
higher level of Cyr61 is found in breast cancer and it is shown to
induce estrogen-independence and to promote invasiveness of
breast cancer [32]. Cyr61 is shown to have elevated mRNA and
protein levels in pancreatic cancer [33]. However, in endometrial
tumor, Cyr61 level is decreased compared to normal endometri-
um [18]. It is also reported that a high Cyr61 level is associated
with a lower risk of recurrence of prostate cancer after surgery
[15]. The involvement of Cyr61 in tumorigenesis has been
mentioned in other investigations. Its exact role is not conclusive.
Cyr61 is critical for pancreatic carcinogenesis through inducing
EMT and stemness [33]. Cyr61 promotes colony formation and
cell growth in esophageal squamous cell carcinoma [34].
However, it has also been reported that Cyr61 suppresses the
growth of non-small-cell lung cancer cells [16].
In our study, it is worth noticing that Cyr61 is expressed
markedly higher in cancer-adjacent hepatic cirrhosis tissue, which
was recognized as precancerous lesions, than in the tumor tissue
itself. These results suggest that the abnormal expression of Cyr61
may be closely related to the development of HCC and hepatic
cirrhosis, and Cyr61 may be involved in the progression of hepatic
cirrhosis to HCC. It is also noted that the expression of Cyr61 is
reduced in poorly differentiated HCC. Similar findings are seen in
colorectal cancer [35] and gastric cancer [36], in which Cyr61 is
over-expressed, while its expression is reduced in more advanced
cancer. This data suggested that Cyr61 might be a helpful early
diagnosis marker for HCC and one of the indicators for the
transformation of liver cirrhosis to HCC.
Figure 2. Over-expression of b-catenin up-regulates Cyr61
expression. HepG2 cells were infected with Adb-catenin or AdGFP at
24 hrs after plating. Cells were harvested at 48, 72, and 96 hours after
continuous incubation. RT-PCR was performed to detect the mRNA
levels of b-catenin and Cyr61. PCR products for b-catenin and GAPDH
(A) or Cyr61 and GAPDH (B) from AdGFP and Adb-catenin infected cells
at the indicated time points were resolved on agarose gel. Relative
quantity of b-catenin or Cyr61 mRNA was calculated based on relative
intensity (b-catenin OD/GAPDH OD or Cyr61 OD/GAPDH OD). *, P,0.05,
**, P,0.01.
doi:10.1371/journal.pone.0035754.g002
Cyr61 Is Regulated by Wnt and Plays a Role in HCC
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35754The exact role of Cyr61 in human cancers remains largely
undefined. Both inhibitory and promoting effects of Cyr61 on
cancers have been reported. We demonstrated in this study that
Cyr61 protein expression was increased in HCC, which is
consistent with our previous work and that of the others [22,28].
However, some other studies found that Cyr61 was down-
regulated in HCC tumor tissues by quantitative real-time PCR
[19] or cDNA array [37] analysis. There were also studies showing
that no significant expression of Cyr61 was detected in HCC
compared to the normal tissue [21,38]. The reasons for the
discrepancy can be many folds. Difference in recognition of the
boundaries between tumor tissue and tumor-adjacent normal liver
tissue may produce different results among the laboratories.
Regardless that we demonstrated in our studies that HCC of
hepatic cirrhosis or non-cirrhosis origin and the stages of cancer
influence Cyr61 expression. These variations, however, are not
considered in the other reported studies. Experimentally, we
studied both the mRNA and protein levels of Cyr61 in HCC,
HCC adjacent tissue and normal liver tissue.
Feng et al showed that Cyr61 suppressed proliferation of HCC
cell line, and negatively regulated cell motility and invasiveness.
The author concluded that Cyr61 acts as a tumor suppressor in
HCC [19]. Our previously published data had shown that over-
expression of exogenous Cyr61 promoted the proliferation and
Figure 3. Inhibition of b-catenin down-regulates expression of Cyr61. HepG2 cells were infected with Adsib-catenin or AdSES-hus at 24 hrs
after plating. Cells were harvested at 48, 72, and 96 hours after continuous incubation; RT-PCR and Western-blot were performed to assess the mRNA
and protein levels of Cyr61 and b-catenin. PCR products for b-catenin and GAPDH (A) or Cyr61 and GAPDH (B) from AdSES-hus and Adsib-catenin
infected cells at the indicated time points were resolved on agarose gel. Relative quantity of b-catenin or Cyr61 mRNA was calculated based on
relative light intensity (b-catenin OD/GAPDH OD or Cyr61 OD/GAPDH OD). *, P,0.05, **, P,0.01.( C), Western blot analysis of b-catenin and Cyr61 in
AdSES-hus and Adsib-catenin infected cells at the indicated time points. b-actin is used as an internal control. (D), Effect of dnTCF4 expression on b-
catenin/TCF4 complex activity in HepG2 cells. HepG2 cells were infected with AdTOP-Luc, luciferase activities were measured following AddnTCF4 or
AdGFP infection at 30 hours, as described in the Materials and Methods. **, P,0.01.( E), Expression of Cyr61 protein in response to the change of b-
catenin/TCF4 complex activity. HepG2 cells were infected with AddnTCF4 or AdGFP at 24 hrs after plating. Cells were havested at 48 and 72 hours
after continuous incubation, and Western-blot was performed to assess the levels of Cyr61 protein. b-actin is used as an internal control.
doi:10.1371/journal.pone.0035754.g003
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repeated our experiments for the effect of Cyr61 on the growth of
HepG2 cells xenografts in SCID mice. Our results indicate that
Cyr61 can promote the proliferation of HepG2 cells not only in
vitro but also in vivo. Animal experiments are in general considered
as a better assessment for tumor development than the in vitro
experiments. Overall, we believe that our conclusion is supported
by our in vitro and in vivo findings.
Cyr61 is known to interact with various integrins, including
acb3, a6b1, acb5 and aIIb3, which leads to a variety of biological
activities, including cell adhesion, migration, and invasion [39].
Furthermore, several studies showed that Cyr61 can be activated
under hypoxia or trauma and is involved in angiogenesis [40] and
cancer cell invasion [41]. The complex function of Cyr61 makes it
difficult to simply define it as an oncogene or a tumor suppressor
gene in the development of hepatocellular carcinoma. It likely has
a variety of functions in the development of HCC at different
stages and may work with a variety of factors.
In summary, our study indicates that Cyr61 is a target gene of
b-catenin signaling in HCC. Over-expression of Cyr61 is induced
by abnormal expression of b-catenin and promotes the growth and
migration of HCC cell line in vitro and the progression of HCC
xenografts in SCID mice. Based on our results, it is reasonable to
hypothesize that early interference with Cyr61 signaling pathway
may prevent the transition from hepatic dysplasia to HCC. Future
studies about the complex role and mechanism of Cyr61 in
tumorigenesis and progression of HCC are needed.
Materials and Methods
Ethics Statement
The experimental protocols were approved by the Ethical
Committee of Third Military Medical University (TMMU).
Verbal consent was obtained from all patients and guardians
prior to the procedure. Written consent, which contains many
personal information, may impact the lives of patients. So, we
Figure 4. The transcription of human Cyr61 is activated by b-catenin/TCF4 complex. (A), Diagram of two putative TBEs in the Cyr61
promoter. TBE1 (CTTTGAA) is located at 2660 bp upstream of the transcription start site, whereas TBE2 (AACTTTG) was located at 2710 bp upstream
of the transcription start site. (B), Schematic representation of luciferase reporter constructs from the Cyr61 promoter containing TBEs, TBE mutation
constructs (mut-TBE1, mut-TBE2, Double-mutTBE). (C), Binding of b-catenin/TCF4 complex to the promoter of Cyr61 in vivo. HepG2 cells were
infected with Adb-catenin for 36 hrs followed standard ChIP procedure using anti-b-catenin antibody or control IgG as described in Material and
Methods. The chromatin DNA fragments were used for PCR amplifications with a pair of primers specific for the Cyr61 promoter containing the two
TBEs. lane I, IgG; lane B, Anti-b-catenin; In, Input. (D), Effect of b-catenin on Cyr61 promoter activity in 293 cells. Cells were co-transfected with
luciferase reporter construct and Adb-catenin, AdGFP, or AddnTCF4, luciferase activities were measured after 30 hours’ transfection. Renilla reniformis
luciferase reporter (pRL) was used as an internal control. Results were shown as an average of three independent experiments. *, P,0.05, **, P,0.01,
compared with pGL3-TBE stimulated with b-catenin. (E), Effect of b-catenin on Cyr61 promoter activity in HepG2 cells. Cells were transfected with
luciferase reporter construct (pGL3-TBE, pGL3-mutTBE1, pGL3-mutTBE2, pGL3-D-mutTBE), luciferase activities were measured after 30 hours’
transfection. Renilla reniformis luciferase reporter (pRL) was used as an internal control. Results were shown as an average of three independent
experiments. *, P,0.05 compared with pGL3-TBE.
doi:10.1371/journal.pone.0035754.g004
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approved by the Ethical Committee of Third Military Medical
University.
All animal protocols were approved by the Ethical Committee
of Third Military Medical University (approval number:
2009020015).
Human tumor samples
All patients samples were collected from the First Affiliated
Hospital of TMMU. Complete clinical data and pathological
grade were also available for all patients. Among the collected
samples, 35 cases (30 male and 5 female) of HCC, with patients
aging from 28 to 73 years old (an average of 49.8), were paraffin-
embedded tissues. 30 cases (male) of hepatic cirrhosis of paraffin-
embedded cancer-adjacent tissues, aging from 39 to 67 years old
(an average of 50) were collected from the Department of
Pathology. All these specimens were subjected to histological
examination and immunohistochemistry studies. 27 cases of
surgical resection HCC and HCC adjacent specimens (23 male
and 4 female), with age ranging from 26–68 years old (an
average of 50), were acquired from the Department of
Hepatobiliary Surgery. Five cases of normal liver samples were
obtained from deceased liver donors. Liver tissue samples were
fixed in 4% formalin for histological examination and immuno-
histochemistry, and were used to justify for final diagnoses. None
of the patients had received preoperative chemotherapy or
radiation therapy.
Cell lines and cell culture
The cell lines HepG2 and HEK293 were obtained from
Shanghai Cell Bank (Shanghai). HepG2 cells were cultured in
RPMI1640 supplemented with 10% heat-inactivated fetal calf
serum, 100 units/ml penicillin and 10 mg/ml streptomycin at
37uC in a humidified 5% carbon dioxide atmosphere. HEK293
cell line was cultured in DMEM supplemented with 10% heat-
inactivated fetal calf serum, 100 units/ml penicillin and 10 mg/ml
streptomycin at 37uC in a humidified 5% carbon dioxide
atmosphere.
Immunohistochemical staining
Analysis of b-catenin and Cyr61(Abcam) expression was
performed on the paraffin section of human liver tissues. The
staining procedure was conducted as decribed previously [28].
Slides were evaluated using a standard bright field microscope.
Digital images were then acquired using the NIS-Element Imaging
Analysis System (Nikon, Japan). Positive staining was defined as
more than 10% of cells containing brown color. The degree of the
staining was digitalized automatically using NIS-Element Imaging
Analysis System once the positive and negative points were
defined. The mean density of random five microscopic fields was
calculated which reflects the relative expression level of b-catenin
or Cyr61. Results were shown as (mean6S.D).
Transient infections
HepG2 cells were seeded in six-well plates. At 80% confluence,
cells were infected with adenovirus expressing various genes
Figure 5. Cyr61 promotes growth of HCC xenograft. HCC xenograft models were established by subcutaneous injection of HepG2 cells
infected with AdCyr61 or AdRFP for 36 hrs prior to injection. Two groups of SCID mice (n=4/group) were injected with 5.0610
6 cells per mouse. (A),
Cyr61 levels in HepG2 cells infected with AdCyr61 and AdRFP. (B), Animals and their tumor tissues at 21 days after injection. (C), H&E staining of
tumor tissues showed fibrous connective tissues hyperplasia, inflammatory cell infiltrating and tumor cells with multinuclear in xenograft tumor
samples (4006), F: fibrillar connective tissue, T: tumor. Immunohistochemical detection of Ki67 in xenograft tumor samples (4006). (D), Tumor sizes
were measured at a 3-day interval starting from day 6 after injection. The graph shows the tumor volume for each treatment group. *, P,0.05.
doi:10.1371/journal.pone.0035754.g005
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(negative control siRNA), AddnTCF4 or AdGFP, AdCyr61 or
AdRFP, respectively. After infection, cells were harvested at 48 h,
72 h and 96 h for subsequent analysis.
Plasmid constructs and reporter assays
To determine if over-expression of b-catenin affected Cyr61
promoter activity directly, we construct a luciferase reporter
pGL3-TBE. The fragment extending from 2750 bp to 2600 bp
upstream of the transcriptional start site of human Cyr61
promoter, which contains two TBEs, was generated by PCR
amplification with the following primers: sense: 59-CGGGGTAC-
CATGCCACTGTGGGTATTAATTTG-39, anti-sense: 59-
TCCCCCGGGTGA AAGAGTAGAACGGGGAAGA-39. The
PCR product was cloned into pGL3 using KpnI and SmaI. Point
mutations in the putative TCF-binding site(TBE) were generated
from the pGL3-TBE luciferase reporter plasmid according to the
manufacturer’s recommendations (Stratagene, QuikChange mu-
tagenesis kit). 293 cells were seeded in twenty-four-well plates and
cultured up to 80% confluence, at which point they were infected
with Adb-catenin, AdGFP, or AddnTCF4, and at the same time,
transfected with a luciferase reporter construct (pGL3-TBE,
pGL3-mutTBE1, pGL3-mutTBE2, pGL3-D-mutTBE) using Li-
pofect2000. HepG2 cells were seeded in twenty-four-well plates
and cultured up to 80% confluence, at which point they were
transfected with a luciferase reporter construct (pGL3-TBE,
pGL3-mutTBE1, pGL3-mutTBE2, pGL3-D-mutTBE) using Li-
pofect2000. Renilla luciferase reporter was used as internal
control. Thirty hours after infection, luciferase assay was
performed using the Dual Luciferase Assay System Kit (Promega).
All experiments were performed in triplicate. Results are shown in
means 6 S.D.
Luciferase Reporter Assay
Luciferase reporter construct TOP-Luc containing three copies
of the Tcf/Lef sites upstream of a thymidine kinase (TK) promoter
and the firefly luciferase gene(AdTOP-Luc) was used to examined
the effect of the dominant negative TCF4 (dnTCF4) on b-catenin/
TCF4 transactivation activity. HepG2 cells were seeded in 24-well
plates. At 80% confluence, cells were infected with AddnTCF4 or
AdGFP. Twenty-four hours after infection, cells were infected with
AdTOP-Luc. Thirty hours after infection, luciferase assays were
performed, using Luciferase Assay System kit, in accordance with
the manufacturer’s protocols (Promega). All experiments were
performed in triplicate. Results are shown in means 6 S.D.
Reverse Transcription-PCR (RT-PCR)
cDNA was synthesized using oligo (dT20) with a Superscript
RT-PCR kit (TOYOBO Japan). The generated cDNA was
amplified using gene-specific primers: b-catenin 59-
AAAGCGGCTGTTAGTCACTGG-39 and 59-GACTTGG-
GAGGTATCCACATCC-39; Cyr61 59-ACTTCATGGTCC-
CAGTGCTC-39 and 59-AAATCCGGGTTTCTTTCACA-39;
GAPDH 59-CATCATCTTCCAGGAGCG-39 and 59-
TGACCTTGCCCACAGCCTTG-39.
Western blot analysis
Cell lysates were prepared with cell lysis buffer containing a
protease inhibitor cocktail (Roche). 50 mg of total protein for each
sample was loaded onto 8% SDS-PAGE and transferred to PVDF
membrane. The membrane was incubated with antibody against
b-catenin or Cyr61 at a dilution of 1:1000 or 1:2000 respectively.
After the blots were incubated with horseradish peroxidase-
conjugated secondary antibody, immune-reactive signals were
detected using ECL kit (Millipore America).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assay was carried out
as described previously [25]. A pair of primers specific for the
human Cyr61 promoter, located from 2750 bp to 2600 bp
relative to the transcription start site of Cyr61, were used for PCR
amplification. Primer was 59-ATGCCACTGTGGGTAT-
TAATTTG-39 and 59-TGAATGAAAGAGTAGAACGGG-
GAAG A-39.
Animal models experiments
After infected with AdCyr61 or AdRFP for 36 h, HepG2 cells
were subcutaneously injected into the flank of 4-week-old SCID
mice (Experimental Animal Center, Third Military Medical
University, ChongQing, China), at 5.0610
6 cells per mouse.
Tumor size of each mouse was measured every three days
regularly, and the tumor volume was estimated with the formula
a6b
260.5, where a and b represent the maximal and minimal
diameters respectively. Mice were euthanized on day 21, and
tumor masses were retrieved for histological analysis and
immunohistochemical staining of Ki67. Growth curves were
plotted using tumor volume for each experimental group at the
set points.
Statistical analysis
Data is expressed as mean 6 standard deviation (S.D.).
Statistical analysis of the data was performed with the Student
paired t test, the 2-tailed Student t test at a statistical level of
P,0.05 or P,0.01. The average absorption of the immunohis-
tochemistry staining for the matched patient samples was
compared using the K Pearson test at a statistical level of
P,0.01. SPSS software version 13.0 was used to analyze these
data.
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